Antitumor agent for thyroid cancer

• US 9,006,256 B2
• Filed: 04/08/2011
• Issued: 04/14/2015
• Est. Priority Date: 05/18/2006
• Status: Active Grant

• Current Assignee: Eisai R & D Management Company Limited (Eisai Medical Research Incorporated)
• Original Assignee: Eisai R & D Management Company Limited (Eisai Medical Research Incorporated)
• Inventors: Matsui, Junji
• Primary Examiner(s): Gembeh, Shirley V
• Application Number:
  US13/083,338
• Publication Number:
  US 20110207756A1
• Time in Patent Office: 1,467 Days
• Field of Search: 514/266.2, 514/312, 312/414
• US Class Current: 514/266.2
• CPC Class Codes: A61K 31/47 Quinolines; Isoquinolines
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/18 of the parathyroid hormones
• CPC Class Codes: C07D 215/22 attached in position 2 or 4
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Abstract

The present invention provides pharmaceutical compositions and therapeutic methods for treating diseases such as multiple endocrine neoplasia type IIA, multiple endocrine neoplasia type IIB, familial medullary thyroid carcinoma, thyroid carcinoma, papillary thyroid carcinoma, sporadic medullary thyroid carcinoma, Hirschsprung disease, pheochromocytoma, parathyroid hyperplasia and mucosal neuromas of the gastrointestinal tract. The therapeutic methods and pharmaceutical compositions use a RET kinase inhibiting substance, such as 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and pharmacologically acceptable salts thereof, and involve a step of administering the RET kinase inhibiting substance to a patient.

Claims

1. A method for treating at least one disease selected from the group consisting of multiple endocrine neoplasia, type IIA, multiple endocrine neoplasia, type IIB, familial medullary thyroid carcinoma, papillary thyroid carcinoma, sporadic medullary thyroid carcinoma, Hirschsprung disease, pheochromocytoma, parathyroid hyperplasia and mucosal neuromas of the gastrointestinal tract, the method comprising the step of administering an effective amount of an RET kinase inhibiting substance to a patient in need thereof, wherein said RET kinase inhibiting substance is

4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or a pharmacologically acceptable salt thereof.

2. The method according to claim 1, wherein the RET kinase inhibiting substance is a mesylate salt of the compound 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.

3. A method for treating thyroid carcinoma, comprising administering an effective amount of an RET kinase inhibiting substance to a patient in need thereof, wherein said RET kinase inhibiting substance is

4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide

or a pharmacologically acceptable salt thereof.

4. The method according to claim 3, wherein the RET kinase inhibiting substance is a mesylate salt of the compound 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.

5. A method for treating a disease, comprising the step of administering an effective amount of an RET kinase inhibiting substance to an organism comprising a cell expressing mutant RET, wherein said RET kinase inhibiting substance is

4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or a pharmacologically acceptable salt thereof.

6. The method according to claim 5, wherein the RET kinase inhibiting substance is a mesylate salt of the compound 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.